A clinical trial focusing on using a long peptide vaccine to treat resected high-risk melanoma showed that co-administering poly ICLC and incomplete Freund’s adjuvant, compared to solely employing the TLR7/8 agonist resiquimod, amplified the CD8+ T-cell immune response rate (NCT02126579).579 Consistently, in another clinical study, the NY-ESO-1 Protein Vaccination elicited a CD8+ T cell response only when combined with resiquimod (3 out of 12, 25%), though the sample size was limited.580. The gene discussed is CD8A; the disease is melanoma.